CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in India26-03-2024
26-03-2024
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Restructuring
Merger of Cipla Technologies LLC, USA with Cipla USA Inc., USA, wholly owned step down subsidiaries of the Company26-03-2024
CIPLA LTD. - 500087 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
Intimation under Regulation 30 of SEBI Listing Regulation.20-03-2024
Buy Cipla; target of Rs 1700: Sharekhan
Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1700 in its research report dated March 14, 2024.18-03-2024
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Change in Management
Further to the intimation filed on 15th March 2024, with respect to appointment of Mr. Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain of the Company, we are re-submitting the same intimation affixing DSC in compliance with requirement of circulars issued by BSE and NSE. We confirm that there is no change in the information.15-03-2024
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Change in Management
Mr. Sai Venkata Mungara, presently working as Vice-president and Head Regional Supply Chain, North America has been appointed as Senior Management Personnel and Global Head - Supply Chain of the Company w.e.f. 1st April 202415-03-2024
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
In compliance with the provisions of Regulation 30 (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby notify that the Operations and Administrative Committee of the Company on 15th March 2024 has allotted 1,658 fully paid-up equity shares of INR 2 each, pursuant to exercise of ESOPs / ESARs under the Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company. Consequently, the issued, subscribed and paid-up Capital of the Company stands increased to INR 1,61,47,34,124 comprising of 80,73,67,062 equity shares of face value INR 2 each.15-03-2024
Cipla stock jumps to all-time high; Nuvama raises target price, sees 18% upside
Cipla is aiming to transition from a pure-play pharma company to an integrated health player, per analysts.11-03-2024
CIPLA LTD. - 500087 - Disclosure Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
We hereby notify that Goldencross Pharma Limited, wholly owned subsidiary of the Company has completed the sale of its entire shareholding in Wellthy Therapeutics Private Limited, in terms of the definitive agreement executed on 6th March, 2024.06-03-2024